INHIBITION OF STRUCTURAL JOINT DAMAGE WITH UPADACITINIB AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS

被引：0

作者：

Peterfy, Charles G. ^{[1
]}

Genovese, Mark C. ^{[2
]}

Song, In-Ho ^{[3
]}

Friedman, Alan ^{[3
]}

Hall, Stephen ^{[4
]}

Mysler, Eduardo ^{[5
]}

Durez, Patrick ^{[6
]}

Baraliakos, Xenofon ^{[7
]}

Enejosa, Jeffrey V. ^{[3
]}

Shaw, Tim ^{[3
]}

Li, Yihan ^{[3
]}

Chen, Su ^{[3
]}

Strand, Vibeke ^{[2
]}

机构：

[1] Spire Sci Inc, Kentfield, CA USA

[2] Stanford Univ, Palo Alto, CA 94304 USA

[3] AbbVie Inc, N Chicago, IL USA

[4] Monash Univ, Cabrini Hlth & Emeritus Res, Malvern, Australia

[5] Org Med Invest, Buenos Aires, DF, Argentina

[6] Catholic Univ Louvain, Clin Univ St Luc, Brussels, Belgium

[7] Herne & Ruhr Univ, Bochum, Germany

来源：

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2020年 / 26卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

128

引用

页码：9 / 10

页数：2

共 50 条

[21] Clinical efficacy of combination therapy of prospidin and methotrexate vs monotherapy of methotrexate for rheumatoid arthritis
Nemtsov, BF
Simonova, OV
Politova, NN
Benenson, EV
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 168 - 168
[22] Early rheumatoid arthritis:: combination therapy of doxycycline plus methotrexate versus methotrexate monotherapy
Alarcón, GS
NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2006, 2 (06): : 296 - 297
[23] COST EFFECTIVENESS ANALYSIS OF UPADACITINIB AND METHOTREXATE FOR PATIENTS WITH METHOTREXATE-RESISTANT RHEUMATOID ARTHRITIS
Jadhav, S.
Yang, Y.
VALUE IN HEALTH, 2020, 23 : S217 - S217
[24] Treating rheumatoid arthritis with leflunomide monotherapy versus combination therapy with methotrexate
Guadagnin, Daniel Ampessan
Mazzali, Leonardo Vinicius
Skare, Thelma Larocca
Kahlow, Barbara Stadler
EUROPEAN JOURNAL OF RHEUMATOLOGY, 2021, 8 (01) : 12 - 15
[25] Clinical remission and progression of joint damage with initial monotherapy or combination therapy in early rheumatoid arthritis
De Vries-Bouwstra, J. K.
Goekoop-Ruiterman, Y. P. M.
Van Zeben, D.
Kerstens, P. J. S. M.
Ewals, J. A. P.
Hazes, J. M. W.
Breedveld, F. C.
Dijkmans, B. A. C.
Allaart, C. F.
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 186 - 187
[26] Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program
Peterfy, Charles G.
Strand, Vibeke
Friedman, Alan
Hall, Stephen
Mysler, Eduardo
Durez, Patrick
Baraliakos, Xenofon
Enejosa, Jeffrey, V
Shaw, Tim
Li, Yihan
Chen, Su
Song, In-Ho
RHEUMATOLOGY, 2022, 61 (08) : 3246 - 3256
[27] UPADACITINIB MONOTHERAPY IN METHOTREXATE-NAIVE PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS AT 72 WEEKS FROM SELECT-EARLY
Van Vollenhoven, R.
Takeuchi, T.
Rischmueller, M.
Blanco, R.
Xavier, R.
Howard, M.
Friedman, A.
Song, Y.
Strand, V.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 330 - 331
[28] THE LITHE STUDY DEMONSTRATES THAT TOCILIZUMAB INHIBITS STRUCTURAL JOINT DAMAGE IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO METHOTREXATE
Kremer, J. M.
Fleischmann, R. M.
Halland, A. M.
Brzezcki, J.
Woodworth, T.
Fisheleva, E.
Alecock, E.
Burgos-Vargas, R.
RHEUMATOLOGY, 2009, 48 : I93 - I93
[29] Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naive Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study
Takeuchi, Tsutomu
Rischmueller, Maureen
Blanco, Ricardo
Xavier, Ricardo M.
Ueki, Yukitaka
Atsumi, Tatsuya
Chen, Su
Friedman, Alan
Pangan, Aileen L.
Strand, Vibeke
van Vollenhoven, Ronald F.
MODERN RHEUMATOLOGY, 2021, 31 (03) : 534 - 542
[30] A COMPARATIVE ANALYSIS OF UPADACITINIB MONOTHERAPY AND UPADACITINIB COMBINATION THERAPY FOR THE TREATMENT OF RHEUMATOID ARTHRITIS FROM TWO PHASE 3 TRIALS
Buch, Maya H.
Wells, Alvin F.
Rubbert-Roth, Andrea
Jaiff, Manish
Schlacher, Casey
Camp, Heidi S.
Li, Yihan
Song, Yanna
Nash, Peter
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 10 - 10

← 1 2 3 4 5 →